Propranolol for treatment of ulcerated infantile hemangiomas

• Published in: Journal of the American Academy of Dermatology Vol. 64; no. 5; pp. 827 - 832
• Main Authors: Saint-Jean, Mélanie, MD, Léauté-Labrèze, Christine, MD, Mazereeuw-Hautier, Juliette, MD, Bodak, Nathalie, MD, Hamel-Teillac, Dominique, MD, Kupfer-Bessaguet, Ingrid, MD, Lacour, Jean-Philippe, MD, Naouri, Michaël, MD, Vabres, Pierre, MD, Hadj-Rabia, Smail, MD, Nguyen, Jean-Michel, MD, Stalder, Jean-François, MD, Barbarot, Sébastien, MD
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01.05.2011; Elsevier
• Subjects: Adrenergic beta-Antagonists - administration & dosage; Adrenergic beta-Antagonists - therapeutic use; Biological and medical sciences; Child; Child, Preschool; Dermatology; Female; General aspects; Head and Neck Neoplasms - drug therapy; Hemangioma - complications; Hemangioma - drug therapy; Hemangioma - pathology; Humans; infantile hemangioma; Male; Medical sciences; propranolol; Propranolol - administration & dosage; Propranolol - therapeutic use; Retrospective Studies; Skin Neoplasms - drug therapy; Skin Ulcer - drug therapy; Skin Ulcer - etiology; Treatment Outcome; ulceration; Wound Healing - drug effects; ulceration; FPDL; flashlamp pulsed-dye laser (therapy); infantile hemangioma; propranolol; IH; Human; Vascular disease; Angioma; Treatment; Dermatology; Cardiovascular disease; Antiarrhythmic agent; Propranolol; Ulceration; Child

Background Ulcerated infantile hemangiomas (IH) are a therapeutic challenge. Propranolol, a nonselective beta-blocker, was recently introduced as a novel treatment for IH. Objective To evaluate our experience of propranolol in the management of ulcerated IH. Methods A national, multicenter, retrospe...